Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer.
Safa MajeedMansi K AparnathiKevin C J NixonVidhyasagar VenkatasubramanianFariha RahmanLifang SongJessica WeissRanya BarayanVijithan SugumarSamir H BarghoutJoel D PearsonRod BremnerAaron D SchimmerMing-Sound TsaoGeoffrey LiuBenjamin H LokPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
TAK-243 displays efficacy in SCLC preclinical models. Enrichment of gene sets is associated with TAK-243 sensitivity and resistance. TAK-243 exhibits synergy when combined with genotoxic therapies in cell lines and PDXs. TAK-243 is a potential therapeutic strategy to improve SCLC patient outcomes, both as a single agent and in combination with existing therapies.